invoX Pharma Ltd (invoX) was incorporated in March 2021 and is a wholly-owned subsidiary of Sino Biopharmaceutical Limited, a global top 50 pharmaceutical company with more than 24,000 employees. Our main goal is to become a fully integrated biopharmaceutical company with an advancing pipeline of innovative products addressing unmet healthcare needs, worldwide.
Our core team is made up of a multicultural international group of highly experienced individuals with life sciences and technology-centered backgrounds, all with a mutual passion and ambition for creating something different.
We are well on our way, through multiple acquisitions and investments, to create a scalable platform to build a portfolio of promising clinical and pre-clinical stage drug candidates, which we believe will improve people’s lives by creating access to innovative medicine across some of our key therapeutic areas including oncology and respiratory.
We aspire to improve people’s lives by creating access to innovative medicine.
invoX is to be a globally recognized, fully integrated pharmaceutical company with an advancing pipeline of innovative products addressing unmet healthcare needs